Patents Assigned to Virion Therapeutics, LLC
  • Adenoviral vectors encoding hepatitis B viral antigens fused to herpes virus glycoprotein D and methods of using the same
    Patent number: 11850282
    Abstract: Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.
    Type: Grant
    Filed: February 24, 2022
    Date of Patent: December 26, 2023
    Assignees: Virion Therapeutics, LLC, The Wistar Institute
    Inventors: Hildegund C J Ertl, Colin Stephen Magowan
  • Adenoviral vectors encoding hepatitis B viral antigens fused to herpes virus glycoprotein D and methods of using the same
    Patent number: 11291716
    Abstract: Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: April 5, 2022
    Assignees: Virion Therapeutics, LLC, The Wistar Institute
    Inventors: Hildegund C J Ertl, Colin Stephen Magowan